Opinion

Video

Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

Panelists discuss how hesitancy in prescribing amyloid-targeting therapies stems from multiple factors including concerns about ARIA adverse effects, modest clinical efficacy data, high treatment costs and limited insurance coverage, logistical challenges of regular infusions and monitoring, infrastructure requirements for specialized imaging, uncertainty about long-term benefits, and the need for careful patient selection within appropriate disease stages.

Video content above is prompted by the following:

  • What factors contribute to hesitancy in prescribing amyloid-targeting therapies?

Related Videos
5 experts are featured in this series
4 experts are featured in this series.
5 experts are featured in this series
Dr Johnie Rose
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Andrew Evens, DO
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
4 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo